Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Small Intestine

Small Intestine

Recruiting

Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection

The purpose of this study is to compare the effectiveness of freeze dried fecal filtrate (no live bacteria) to freeze dried fecal transplant (live bacteria present) in treating recurrent C. difficile infection.

Status
Recruiting
Principal Investigator
Theodore Steiner
Body Locations and Systems
Clostridium Difficile Infections
Area
Vancouver
Age
18 and above

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

The study is to evaluate the long-term safety of oral GED-0301 (mongersen) in subjects with Crohn's Disease.

 

 

Status
Recruiting
Principal Investigator
Baljinder Salh
Body Locations and Systems
Crohn's Disease
Area
Vancouver
Age
18 and above

Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients

Hospitalization for kidney stones in the Inflammatory Bowel Disease (IBD) population is common, particularly among Crohn's patients who had a small bowel resection. This patient population experiences a lifetime occurrence of kidney stone formation as high as 25% accompanied with a high rate of recurrence (the typical rate of stone formation is ~10% in the non IBD population). Giving oral calcium is used to bind oxalate in the intestine in an attempt to reduce the amount of oxalate that is absorbed into the body and to reduce urinary oxalate levels.

Status
Recruiting
Principal Investigator
Ben Chew
Body Locations and Systems
Kidney Stones
Crohn's Disease
Area
Vancouver
Age
19 and above

Closed for Recruitment

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of ABT-494.

Status
Closed for Recruitment
Principal Investigator
Baljinder Salh
Body Locations and Systems
Crohn's Disease
Area
Vancouver
Age
18-75

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

This study is a clinical research study to see if the investigational medication, GED-0301, is effective in participants with active Crohn’s disease. GED-0301 (mongersen) is a drug taken by mouth that inhibits an immune response in the gut (Smad 7) that causes inflammation (or swelling). 

Status
Closed for Recruitment
Principal Investigator
Baljinder Salh
Body Locations and Systems
Crohn's Disease
Area
Vancouver
Age
18 and above

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI). Enrolled subjects will receive one treatment with RBX2660 (microbiota suspension).

Status
Closed for Recruitment
Principal Investigator
Theodore Steiner
Body Locations and Systems
Clostridium Difficile Infections
Area
Vancouver
Age
18 and above

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to anti-Tumor Necrosis Factor (TNF) therapy.

Status
Closed for Recruitment
Principal Investigator
Baljinder Salh
Body Locations and Systems
Crohn's Disease
Area
Vancouver
Age
18-75
Subscribe to Small Intestine

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy